Digipath
Home > Boards > US Listed > Medical - Drugs >

Novartis (NVS)

NVS RSS Feed
Add NVS Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 11/19/2018 11:06:25 AM - Followers: 18 - Board type: Free - Posts Today: 0
Digipath
NVS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVS News: Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder 11/19/2018 06:46:11 PM
NVS News: Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology 11/02/2018 05:27:00 PM
NVS News: Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo du... 10/09/2018 04:53:00 PM
NVS News: Report of Foreign Issuer (6-k) 09/06/2018 07:03:13 AM
NVS News: Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community 07/12/2018 07:15:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#363   WSJ opines on the “new” Novartis: DewDiligence 11/19/18 11:06:25 AM
#362   NVS R&D Day slides (170 pages): DewDiligence 11/05/18 08:53:13 AM
#361   PFE-NVS clinical-trial collaboration in NASH: #msg-144519047. DewDiligence 10/29/18 10:14:56 AM
#360   NVS 3Q18 results: DewDiligence 10/18/18 04:05:46 PM
#359   NVS receives CRL for Ilaris in CVD: #msg-144301592. DewDiligence 10/18/18 10:34:34 AM
#358   NVS acquires ECYT for $2.1B: DewDiligence 10/18/18 10:33:30 AM
#357   AMGN, NVS launch Humira biosimilars in Europe, pursuant DewDiligence 10/16/18 11:24:18 AM
#356   ABBV settles global Humira-patent litigation with NVS: #msg-144157243. DewDiligence 10/11/18 05:24:02 PM
#355   PDUFA date for NVS’ BAF312 in SPMS—>Mar 2019 DewDiligence 10/08/18 10:01:36 AM
#354   Doctors and insurance companies will soon get wise DewDiligence 10/04/18 09:36:05 AM
#353   Entresto will flop debunker1 10/04/18 06:10:41 AM
#352   NVS sells US small-molecule-generics business to India’s Aurobindo DewDiligence 09/06/18 11:18:26 AM
#351   NVS 2Q18 PR: DewDiligence 07/18/18 11:25:34 AM
#350   NVS reports soft 2Q18—but re-iterates full-year guidance: DewDiligence 07/18/18 05:23:02 AM
#348   NVS seeks to divest Alcon—will take enormous loss DewDiligence 06/29/18 09:39:31 AM
#347   Entresto is nothing more than an attempt by debunker1 06/09/18 03:23:21 PM
#346   NVS slides from “Meet the Management” Investor Day: DewDiligence 05/16/18 12:51:12 PM
#345   Data support 12-week dosing of RTH258 for some DewDiligence 04/30/18 04:35:21 PM
#344   FDA approves Tafinlar/Mekinist for adjuvant BRAF-V600+ melanoma: DewDiligence 04/30/18 04:22:15 PM
#343   NVS acquires AVXS for $8.7B in cash: DewDiligence 04/09/18 02:55:20 PM
#342   NVS PR on consumer-JV sale to GSK: DewDiligence 03/27/18 09:44:25 AM
#341   NVS seeking bids for US small-molecule-generics business: DewDiligence 02/16/18 04:27:12 PM
#340   :-) :-) :-) Ecomike 01/24/18 02:33:11 PM
#339   NVS 4Q17 results… DewDiligence 01/24/18 09:10:05 AM
#338   NVS hires oncology chief (from PFE): DewDiligence 01/11/18 10:40:04 AM
#337   Novartis been researching PS Phosphatidylserine targeting ? biopharm 01/06/18 08:11:48 AM
#336   The market is overvalued and overbought, and 2018's sokol 12/29/17 08:53:44 PM
#335   NVS’ Investor Day PR and slides: DewDiligence 11/13/17 02:13:56 PM
#334   https://seekingalpha.com/article/4124174-novartis-looks-challenge-regenerons-tur Inoviorulez 11/13/17 08:13:36 AM
#333   NVS reports full dataset for RTH258-vs-Eylea phase-3 trials: #msg-136129447. DewDiligence 11/11/17 12:28:41 PM
#332   NVS submits Kymriah BLA in adult DLBCL: #msg-135827815. DewDiligence 10/31/17 10:24:00 AM
#331   NVS acquires AAAP for $82/ADS: #msg-135797034. DewDiligence 10/30/17 10:16:23 AM
#330   Merging CRISPR editing and single cell sequencing technologies TERIA 10/26/17 12:20:15 PM
#329   NVS 3Q17 CC slides: DewDiligence 10/24/17 06:57:02 PM
#328   OK, thanks, also looks like it was a Ecomike 10/24/17 12:45:35 PM
#327   NVS delayed the potential Alcon spin-off until 2019. DewDiligence 10/24/17 11:25:06 AM
#326   Why the big drop in NVS today? Ecomike 10/24/17 11:14:32 AM
#325   Vasant Narasimhan becomes CEO 2/1/18—succeeding Joe Jimenez: #msg-134366063. DewDiligence 09/04/17 10:41:21 AM
#324   https://seekingalpha.com/article/4103595-novartis-history-made-future-cancer-tre Inoviorulez 09/01/17 07:42:32 PM
#323   Kymriah/CAR-T outcomes-based pricing: #msg-134254831. DewDiligence 08/30/17 11:22:03 AM
#322   FDA approves NVS’ Kymriah (CTL019 CAR-T) for pediatric ALL: DewDiligence 08/30/17 11:02:14 AM
#321   New drug from Novartis helps prevent heart attacks biotech_researcher 08/27/17 07:51:53 AM
#320   https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-mu Inoviorulez 07/23/17 02:28:42 AM
#319   Sell short this crap along with other big pharma... malt66 07/18/17 08:27:34 PM
#317   NVS 2Q17 CC slides: DewDiligence 07/18/17 01:36:07 PM
#316   https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car Inoviorulez 07/13/17 10:07:15 AM
#315   NVS’ own PR on CTL019 ODAC panel: DewDiligence 07/13/17 09:44:32 AM
#314   FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635. DewDiligence 06/22/17 06:41:33 PM
#313   Ilaris reduces MACE in secondary-prevention setting: #msg-132398529. DewDiligence 06/22/17 09:12:42 AM
#312   RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161. DewDiligence 06/20/17 09:15:40 AM
PostSubject